Mark C. Totoritis

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trial

Kenneth Kalunian, John C. Davis, Joan T. Merrill et al. · Arthritis & Rheumatism · 2002 · 335 citations

Life Sciences, Immunology, Pharmacotherapy +17

A Multicenter Clinical Trial of a Biosynthetic Skin Replacement, Dermagraft-TC, Compared with Cryopreserved Human Cadaver Skin for Temporary Coverage of Excised Burn Wounds

Gary F. Purdue, John L. Hunt, Joseph M. Still et al. · Journal of Burn Care & Rehabilitation · 1997 · 174 citations

Medicine, Plastic Surgery, Surgery +17

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

John C. Davis, Mark C. Totoritis, J. Rosenberg et al. · PubMed · 2001 · 146 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +14

Association of Antibody to Histone Complex H2A–H2B with Symptomatic Procainamide-Induced Lupus

Mark C. Totoritis, Eng M. Tan, Edward M. McNally et al. · New England Journal of Medicine · 1988 · 114 citations

Life Sciences, Immunology, Internal Medicine +15